Short bowel syndrome (SBS): cross-border specialty drug access for international patients

Quick orientation

Short bowel syndrome is uncommon, with prevalence estimates of approximately 30 per million people. Pediatric and adult populations differ in etiology.

Typical age of onset. Following extensive small bowel resection at any age. Pediatric SBS often follows necrotizing enterocolitis or congenital anomalies.

Severity tiers. Severity depends on remaining bowel length and adaptation. Severe forms require lifelong parenteral nutrition.

Why specialty drugs for Short bowel syndrome (SBS) are hard to access internationally

Gattex (teduglutide) is a GLP-2 analog that reduces parenteral nutrition dependence in SBS. International registration is in select markets. The drug requires lifelong dosing and supply continuity is essential.

Treatments approved by the FDA

• Gattex (teduglutide) — FDA approval: 2012. Mechanism: GLP-2 analog. Route: Subcutaneous injection daily. US WAC ballpark: Approximately USD 290,000 per year. Country pricing: Qatar · Kuwait · Jordan · Bahrain · Oman.
• Encelto (revakinagene taroretcel-lwey, ocular indication; included for ATMP context) — FDA approval: 2025. Mechanism: Cell-based therapy for ocular surface disease (representative ATMP). Route: Surgical implantation. US WAC ballpark: Approximately USD 600,000 per treatment. Country pricing: Saudi Arabia · India · Qatar · Kuwait · Jordan · Bahrain.

Cross-border pathways used for Short bowel syndrome (SBS)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm SBS diagnosis and parenteral nutrition dependence.
• Document remaining bowel anatomy.
• Pediatric and adult GI specialist co-management.
• Monitor for fluid and electrolyte changes during titration.
• Pancreatic and gallbladder imaging at baseline per label.

Common questions

How is response measured?

Reduction in parenteral nutrition volume and frequency, weight stability, and quality of life.

Is Gattex available in my country?

Registration varies. We confirm by destination.

How long is treatment?

Generally long-term; some patients can be weaned with sustained response.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Treating GI specialist's prescription, bowel anatomy details, parenteral nutrition history, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Short bowel syndrome (SBS), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Short bowel syndrome (SBS)

Reserved for you.